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To determine the feasibility and safety of deployment 
of this new stent, we deplo ed 28 AVE Micro stents in 
23 native coronary artery esions in 20 patients who r 
developed acute or threatened closure after balloon 
angioplasty (BA). Ten stents were deployed in the left 
anterior descending artery, 10 in the circumflex, and 
8 in the right coronary cktery. Luminal dimensions were 
measured using a computer-based quantitative coro- 
nary angiographic analysis system (CAAS II). Stent 
deployment was successful in 27 of 28 attempts (96%). 
In 1 tient with a threatened closure of the left ante- 
rior c!? escending artery associated with proximal vessel 
tortuosity, attempted stent deployment was unsuccess- 
ful. The clinical course of the other 19 patients in whom 
stent deployment was successful was free of coronary 
reintervention, bypass surgery, and death. A myocar- 
dial infarction was observed in 2 patients (lo%), in 1 
of whom the stent was implanted within 24 hours after 
the onset of acute myocardial infarction, and in the oth- 
er acute vessel occlusion was present for 58 minutes 
before stent implantation. No subacute occlusion was 
observed. Event-free survival at 30 days after stent 
implantation was 85% (17 of 20 patients). Minimal 
luminal diameter was 0.85 f 0.57 mm before and 1.19 
+ 0.66 mm after BA, 2.61 + 0.39 mm during balloon 
inflation, 3.26 + 0.46 mm during and 2.74 f 0.51 mm 
after stenting, 3.43 f 0.52 mm during balloon infla- 
tion after stenting (Swiss Kiss), and 2.85 + 0.48 mm 
after Swiss Kiss. Average percent diameter stenosis was 
reduced from 69% before through 56% after BA to 17% 
after stenting. During the initial stent implantation, stent 
recoil was 0.52 f 0.30 mm (16 & 9% of minimal lumi- 
nal diameter during stent inflation). A Swiss Kiss was 
performed in 14 stents with an average pressure of 14 
f 4 atm, and residual stenosis was reduced from 2.55 
mm (21% diameter stenosis) to 2.85 mm (15% diame- 
ter stenosis) in these lesions. Angiogra hit success 
(~30% residual diameter stenosis) was ac R ieved in all 
stented lesions. The results of this early experience 
would indicate that the new AVE Micro stent may be 
deployed with a high procedural success rate and a 
minimal learning curve. implantation of the stent for 
the bailout management of failed BA can be achieved 
with a low incidence of adverse cardiac events and a 
high angiographic success rate. 
(Am J Cardiol 1995;76:112-116) 
0 ne of the major risks associated with balloori angio- plasty (BA) is acute or threatened closure of the 
coronary artery. When acute coronary occlusion persists 
after balloon dilatation, 20% to 40% of patients sustain 
a myocardial infarction and 4% to 8% of patients die.lA 
Several nonrandomized studies have suggested that de- 
ployment of the WaIlstent,S,6 Gianturco-Roubin stent,7-” 
or Pahnaz-Schatz stent12-14 may be of value in bailout 
management15J6 of acute or threatened closure after BA. 
A number of second generation stents have recently been 
developed and are currently entering the clinical arena. 
One of the most recently developed stents is the AVE 
Micro stent (see Figure 1). This study reports early expe- 
rience with the AVE Micro stent in the clinical arena. 
Clinical events up to 30 days (to cover both the period of 
in-hospital events and period of risk of subacute throm- 
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bosis) are reported as well as the acute angiographic 
results. Quantitative angiographic measurements were 
obtained at 7 intraprocedural phases: before primary BA, 
during primary balloon inflation, after BA at the time of 
acute or threatened vessel closure, during stent inflation, 
after stent deployment, during high-pressure intrastent 
balloon Mation (Swiss Kiss), and finally after Swiss Kiss, 
using a quantitative coronary angiographic analysis sys- 
tem (CAAS II). 
METHODS 
Patients: To determine the feasibility and safety of 
deployment of this new stent, we placed 28 AVE Micro 
stents in 23 native coronary artery lesions in 20 patients 
who developed acute or threatened closure after BA. The 
average age was 56 + 7 years (range 45 to 68), and 17 
patients were men. Thirteen patients had stable angina 
and the remaining 7 patients had unstable angina.” Of 
the 7 patients with unstable angina, 4 had Braunwald 
type II and 3 had type III angina.” 
Criteria of acute and threatened vessel closure: After 
BA, lesion morphology was categorized according to the 
dissection criteria proposed by Huber et al,18 and coro- 
nary flow distal to the lesion was classified according to 
the Thrombolysis in Myocardial Infarction trial (TIMI) 
criteria.19 Acute occlusion was defined as TIM1 0 flow. 
Threatened closure was defined as TIM1 1,2, or 3 flow, 
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with visible dissection type C, D, E, or F, or as dissec- 
tion type A or B and TIM1 1, 2, or 3 flow with a resid- 
ual diameter stenosis of >50%.18~1g 
Stent design: This short stent is characterized by a 
simple balloon-expandable deployment technique, and 
O.OOS-inch stainless teel struts with moderate radiopac- 
ity and a zigzag structure. The metallic surface area in 
the expanded state has been found in vitro to be 8.4% 
for the stent with a 3.5 mm diameter. This stent is com- 
posed of 4 mm welded and unconnected segments pro- 
viding a range of lengths from 4 to 16 mm (Figure 1). 
Balloon angioplasty and stent implantation: BA and 
stent deployment (Figure 1) were performed according 
to standard clinical practice by the femoral approach at 
the Thoraxcenter (Rotterdam, The Netherlands). The 
coronary stents were delivered on a premounted balloon 
catheter. The size of the balloon is 0.25 mm larger than 
the stent diameter to allow for stent recoil. Selection of 
the nominal stent size was determined to match the ves- 
sel reference diameter obtained from on-line quantita- 
tive angiographic measurement. Of the 28 stents used in 
23 lesions, 9 had a 3 mm diameter, and 15 had a 3.5 mm 
and 4 a 4 mm diameter. Of the 28 stents 7 were 4 mm 
in length, 17 were 8 mm, 2 were 12 mm, and 2 were 16 
mm. During primary BA, the nominal balloon diameter 
was 2.98 f 0.41 mm, and the maximal inflation pressure 
given was 9.3 + 3.0 atm. After initial deployment of the 
stent, high-pressure inflations (14.6 r 3.5 atm) to opti- 
mize stent expansion (Swiss Kiss) were obtained with 
balloons with 3.50 k 0.55 mm nominal diameter. 
Anticoagulant therapy: At the beginning of the pro- 
cedure, patients were given an intravenous bolus dose 
of 10,000 IU of heparin, and subsequently 5,000 IU, as 
required, to maintain the activated clotting time of >300 
seconds throughout the procedure. The postintervention 
anticoagulant regimen was conventiona120: One hour 
after removal of the femoral sheath, a heparin intrave- 
nous infusion was begun to maintain the activated par- 
tial thromboplastin time between 70 and 90 seconds until 
oral anticoagulant herapy (warfarin) had achieved a pro- 
thrombin time international normalized ratio of 2.5 to 
3.5. Warfatin was prescribed for 3 months after stent im- 
plantation, and aspirin indefinitely.20 
Quantitative coronary angiographic analysis: The new 
version of the CAAS II analysis21,22 was used to per- 
form quantitative analysis. In the CAAS II analysis, 
which has previously been described elsewhere,22-24 
the entire cineframe of 18 X 24 mm is digitized at a reso- 
lution of 1,329 X 1,772 pixels. Correction 
for pincushion distortion is performed 
Study end points and definitions: The primary clini- 
cal end point of the study was the occurrence of any of 
the following adverse cardiac events: acute or subacute 
stent thrombosis, repeat intervention, coronary artery 
bypass surgery, myocardial infarction, or death. Proce- 
dural success was defined as technically successful 
deployment of the stent in the absence of an adverse car- 
diac event. Angiographic success was defined as a ~30% 
residual diameter stenosis after final deployment of the 
stent. Subacute thrombosis was defined as a stent throm- 
bosis within 14 days of deployment. Acute clinical out- 
come included all cardiovascular events occurring with- 
in 1 month of stent deployment. 
Statistical analysis: A paired Student’s t test was used 
to compare sequential changes at the same segment in 
the same patients. A p value co.05 was considered sig- 
nificant. 
TABLE I Angiographic Lesion Characteristics of 23 Narrowings 
Number 
- 
location of narrowings 
Left anterior coronary artery 8 
Right coronary artery 6 
Left circumflex coronary artery 9 
Portion of artery stented 
Ostial or major bifurcation site 9 
Middle segment 14 
Modified AHA/ACC classification* 
Type A 2 
Type Bl 6 
Type B2 9 
Type C 6 
Type of dissection before stentt 
Type A 2 
Type B 4 
Type C 8 
Type D 1 
Type E 7 
Type F 1 
TIMI flow before stent* 
TIMI 0 1 
TIMI 1 0 
TIMI 2 8 
TIMI 3 14 
Thrombus before stentl 7 
Reason for stenting 
Threatened closure 22 
Acute complete occlusion 1 
*American Heart Association/American College of Cardiology Task Force.25 
+Dissection classification.‘* 
*Thrombolysis in Myocardiol Infarction trial flow.‘9 
§Presence of thrombus.26 
befoie analysis. Boundaries of-a selected 
coronary segment are detected automati- 
cally. The absolute diameter (mm) of the 
stenosis is determined using the guiding 
catheter as a scaling device. To standard- 
ize the method of angiographic analysis, 
the following measures were taken: All 
study frames selected for analysis were 
end-diastolic to minimize motion artifact, 
and arterial segments were measured be- 
tween the same identifiable branch points 
at each stage of the procedure. 
FIGURE 1. An 8 mm AVE Micro stent. The AVE Micro sknt is a remounted bal- 
loon-expandable stainless steel stent composed of 4 mm welde 8 or unconnected 
segments. 
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RESULTS 
lesion characteristics: Angiographic characteristics of
the treated lesions are listed in Table I. Of 23 lesions, 8
lesions were in the left anterior descending coronary 
arteries, 6 were in the right coronary arteries, and the re- 
maining 9 were in the circumtlex coronary arteries. Four 
of the lesions were ostial and 5 were at sites of major bi- 
furcation. Before BA, the lesions were categorized ac- 
cording to the American Heart Association/American 
College of Cardiology Task Force criteria.25 Of the 23 
lesions, 2 were type A, 15 were type B, and the remain- 
ing 6 were type C. After primary BA, at the time of acute 
or threatened vessel closure, 2 lesions had a type A dis- 
section (with >50% diameter stenosis), 4 a type B dis- 
section (with >50% diameter stenosis), 8 a type C, 1 a 
type D, 7 a type E, and 1 a type F dissection.18 At this 
prestent phase, TIMI flowlg was grade 0 in 1 lesion, grade 
2 in 8, and grade 3 in 14 lesions, and the angiographic 
appearance of intracoronary thrombus (intraluminal fill- 
ing defect) was present in 7 lesions.26 
Procedural outcome: Stent delivery was possible in 27 
of 28 stents (96%). In 1 patient, the stent could not be 
advanced beyond an oblique curved branch point to the 
target stenosis in the midleft anterior descending artery. 
The unexpanded stent was withdrawn through the guid- 
ing catheter without difficulty and the patient was man- 
aged by emergency bypass surgery, after which the pa- 
tient had no further event. In a second patient, a 12 mm 
stent was deployed at the origin of the left anterior de- 
scending artery. During the process of stent inflation, the 
proximal 4 mm unit of the 12 mm stent migrated prox- 
imally into the mainstem of the left coronary artery. This 
4 mm unit was then expanded fully in the left mainstem 
and the patient had an uneventful clinical course. 
In-hospital events: One patient in whom stent deliv- 
ery was unsuccessful underwent emergency bypass sur- 
gery and had a normal postoperative recovery. The clini- 
cal course of the other 19 patients in whom stent de- 
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ployment was successful was free of coronary reinter- 
vention, bypass surgery, and death. A myocardial in- 
farction was observed in 2 patients (lo%), in 1 of whom 
the stent was implanted within 24 hours after the onset 
of acute myocardial infarction, and in the other patient 
acute vessel occlusion was present for 58 minutes be- 
fore stent implantation. A femoral hemorrhage and hema- 
turia requiring blood transfusion were observed in 1 pa- 
tient (5%). All patients remained event free after hospi- 
tal discharge, and thus the event-free survival at 30 days 
follow-up was 85% (17 of 20 patients). 
Quantitative angiographic analysis: Quantitative angi- 
ographic analysis provided measurements of luminal di- 
ameter at each procedural phase. Minimal luminal diam- 
eter (MLD) was seen to change from 0.85 + 0.57 mm 
before primary BA to 1.19 + 0.66 mm after BA at the 
time of dissection. Implantation of the AVE Micro stent 
increased the MLD to 2.74 + 0.51 mm (p ~0.001). The 
changes in MLD from before primary BA through stent 
implantation to after Swiss Kiss are shown in Figure 2. 
In 14 lesions requiring poststent balloon dilatation (Swiss 
Kiss), the MLD increased significantly from 2.55 f 0.52 
mm (before Swiss Kiss) to 2.85 + 0.48 mm (after Swiss 
Kiss, p ~0.01). The absolute value of the acute stent 
recoil in the initial implantation (MLD during stent infla- 
tion, MLD after stent) was 0.52 f: 0.30 mm, and the acute 
recoil ratio of this stent (MLD during stent inflation, 
MLD after/during stent inflation) was 16 + 9%. An exam- 
ple of the stent implantation in the dissection after BA can 
be seen in Figure 3. Angiographic success was achieved 
in all lesions with successful deployment of the stent. Thus, 
the angiographic success rate of all lesions attempted 
was 96% (22 of 23 lesions). Average percent diameter 
stenosis decreased significantly from 69% before inter- 
vention to a final residual value of 17% after stent deploy- 
ment. Figure 4 shows the sequential changes in percent 
diameter stenosis. Performance of a Swiss Kiss in 14 le- 
sions achieved a further reduction in residual percent 
diameter stenosis from 21% after AVE 
to 15% after Swiss Kiss (p cO.05). 
T 
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,343 
2.94.'. T _t . : y_ 
_,. ‘_ :
1 
2.55 
0’ 
I 
The key Iindings of this early expe- 
rience were as follows: (1) Delivery of 
.. 2.85 the AVE Micro stent o the target lesion 
can be achieved in a high proportion of 
cases (22 of 23 lesions). (2) After deliv- 
ery of the stent (22 lesions), angio- 
graphic success as defmed by ~30% re- 
sidual diameter stenosis can be achieved 
in a high proportion of cases (22 of 22). 
(3) Acute recoil after dilatation of the 
Micro stent in vivo compares favorably 
with other stents.*~** (4) Despite the 
bailout indication for stenting, deploy- 
ment of the Micro stent resulted in a 
low risk of acute or subacute stent 
thrombosis (0 of 22 stented lesions). 
1 I / I I I 
PRE BA POST AVE POST BA POST 
BA STENT AVE POST- SWISB- 
AVE KISS 
FIGURE 2. Changes in minimal luminal diameter (MD) in 23 lesions from before 
(PRE) the procedure through stent implantation to the performance. Swiss Kiss (see 
Successful delivery of the Micro 
text) was performed in 14 lesions. Minimal luminal diameter improved significantly stent may be attributed to 2 character- 
after (POST) AVE stent implantation and after the performance of a Swiss Kiss istics of the stent design. First, the 1.65 
(14.6 f 3.5 atm). BA = balloon angioplasty. mm profile of the Micro stent in its 
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unexpanded balloon-mounted state com- 
pares favorably with that of previous stents, 
and thus an intraprocedural exchange of 
the guiding catheter or guidewire should 
rarely be necessary. Second, the uncon- 
nected junctions of the modules and the 
4 and 8 mm length of the individual mod- 
ules provide the stent with hinge joints 
and very limited rigid segments to aid the 
negotiation of tortuous vessels. Furtber- 
more, these 2 features, in conjunction with 
the primarily longitudinal orientation of 
the stent struts, should permit passage of 
an additional Micro stent through a prox- 
imally placed stent when necessary. The 
proximal migration during inflation of a 
4 mm segment of an unconnected 12 mm 
stent into the left mainstem in 1 of our pa- 
tients, indicates that only connected (weld- 
ed) units of the AVE Micro stent should 
be placed in ostial esions to prevent such 
an occurrence. 
Although 21 of 23 lesions had dissec- 
tion type B, C, D, E, and F after primary 
BA, stenting was effective in tacking back 
the dissection flap and restoring TIM1 3 
flow in all lesions stented. Although 7 of 
the lesions with threatened closure had 
angiographic evidence of intracoronary 
thrombus before stenting, deployment of 
FIGURE ‘3. Coronary angi of the right coronary artery in a tient with 
dissection after angioplasty. Before balloon angiop asty, the p” 
minimal lumina was 0.82 mm w. After Balloon angioplasty, the 
MD increased to 1.38 mm; however, a type C dissection with Thrombolysis in 
Myocardial Infarction trial III flow was present (81. Two AVE Micro stems (each 3 
mm in diameter and 8 mm in length) were de loyed and the moderately 
radiopaque stent struts can be seen during in P- atron of the stent (Cl. After stent 
deployment, the MLD improved to 2.62 mm with resolution of the dissection IDI. 
the Micro stent without the administration of intracoro- 
nary thrombolytic therapy resulted in neither acute nor 
subacute thrombosis during follow-up. The absence of 
stent thrombosis may relate to the low metallic surface 
area of the Micro stent (8.4% for the 3.5 mm stent in 
the expanded state) and the optimal expansion of the 
stent (~30% residual diameter stenosis in all stented 
lesions), with the additional performance, when neces- 
sary, of a Swiss K~ss.~~ 
served when vessel closure persisted for >49 minutes. 
Thus, the elevated creatine phosphokinase levels in our 
2 patients were believed to reflect heir clinical events 
before stent deployment rather than the occurrence of an 
acute or subacute thrombosis after stenting. 
Both single center and multicenter observational series 
of bailout stenting have been reported for the Wallstent, 
Palmaz-Schatz stent,7-U and Gianturco Roubin stent. 12-ld 
These have been associated with a deployment success 
decline after stenting without a further 
Two of our patients (10%) had sig- 
nificantly elevated creatine phospho- 
kinase levels and electrocardiographic 
changes in myocardial infarction. In 1 
of these 2 patients, stent implantation 
was performed within 24 hours of the 
onset of an acute Q-wave myocardial 
infarction, and the patient became 
asymptomatic after stenting and crea- 
tine phosphokinase levels continued to 
_ _ 
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80 - 
69% 
._ 
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40 - 
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:. . . . . 
60 - . . 56% 
--,. _. : 
increase. In the other patient, acute 
vessel closure had been present for 58 
minutes before stent deployment. This 
‘. _ ‘. ‘.., ‘. ., ‘. ._ 21% 
20 - ‘_ T .. .‘..__. .‘...._,. 
patient had no further chest pain after 
stent implantation and the peak crea- 
tine phosphokinase level in this patient 0 
I 
PRE 
lL I 15% 12% I I I 
was 720 ID/L. Lincoff et al9 indicated 
POST POST POST 
BA AVE SWISS-KISS 
that peak creatine phosphokinase lev- 
els directly related to the time of stent 
placement after the onset of vessel clo- FIGURE 4. Changes in percent diameter (%DS) stenosis from before (PRE) the proce- d 
sure and significant creatine phospho- 
ure to after (POST) stent implantation in 23 lesions. A Swiss Kiss with high pres- 
sure (14.6 f 3.5 atm) was performed in 14 lesions and the percent diameter steno- 
kinase elevation was frequently ob- sis improved from 21% to 15%. BA = Balloon angioplasty. 
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rate of 89% to 98%, a myocardial infarction rate of 4% 
to 43%, a bypass surgery rate 1% to 60%, a subacute 
thrombosis rate 7% to 16%, and a mortality rate of 1% 
to 7%. More recently, a number of new stents have be- 
come available for clinical evaluation; these include the 
Cordis and Advanced Cardiovascular Systems stents. 
Whereas the structural design of these stents can be 
grouped into 2 categories of mesh stents and coil stents, 
the AVE Micro stent represents a new design concept. 
Given their fundamental differences in structural design 
(profile in the unexpanded state, longitudinal flexibility, 
mechanism of deployment, metallic surface area in the 
expanded state, interstrut distance, strut orientation, and 
radial strength), each stent will have to prove its own safe- 
ty and efficacy for each clinical indication in prospective 
trials. It is likely that stents with a low metallic surface 
may be more suited to the more thrombogenic substrate 
of bailout stenting, while the more rigid mesh stents with 
higher metallic surface area may be more suited to the 
elective treatment of primary or recurrent stenoses with 
strong elastic recoil in nontortuous vessels. 
This study revealed sequential changes in luminal 
diameter from before primary intervention, through stent 
implantation, to the performance of a Swiss Kiss. Per- 
cent diameter stenosis decreased from 69% (before BA) 
through 56% (after BA) to 15% (after Swiss Kiss). 
Whereas previous in vitro testing of this stent has found 
recoil to be 8.7% for the 3.5 mm diameter stent, in this 
quantitative angiographic study of the stent in diseased 
coronary arteries in vivo, we found recoil to be 16 -I- 9% 
(0.52 mm), with an average stent diameter of 3.41 mm. 
Furthermore, the poststent MLD achieved matched or 
was greater than the nominal stent size in only 3 of 22 
stented lesions. The performance of a high-pressure (14 
atm) Swiss Kiss may result in an increase in MLD by 
0.31 mm, and may be a useful complementary technique 
when on-line quantitative angiographic analysis is avail- 
able to guide the optimization of stent deployment. 
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